Faricimab Treatment of Polypoidal Choroidal Vasculopathy Resistant to Intravitreal Ranibizumab Injections and Ranibizumab Port Delivery (Susvimo).

IF 0.5 Q4 OPHTHALMOLOGY Journal of VitreoRetinal Diseases Pub Date : 2024-08-22 DOI:10.1177/24741264241271739

Jeffrey Bloom, Rami Madani, Ali J Haidar, Tarek Alasil

{"title":"Faricimab Treatment of Polypoidal Choroidal Vasculopathy Resistant to Intravitreal Ranibizumab Injections and Ranibizumab Port Delivery (Susvimo).","authors":"Jeffrey Bloom, Rami Madani, Ali J Haidar, Tarek Alasil","doi":"10.1177/24741264241271739","DOIUrl":null,"url":null,"abstract":"Purpose: To report a case of polypoidal choroidal vasculopathy (PCV) recalcitrant to treatment with ranibizumab and with a ranibizumab port delivery system (Susvimo) but responsive to faricimab-svoa. Methods: A case and its findings were analyzed. Results: A 69-year-old Filipino man with PCV in the left eye was treated for 2 years with multiple ranibizumab intravitreal (IVT) injections followed by ranibizumab port delivery combined with rescue ranibizumab IVT injections, with no significant response clinically or on imaging. The visual acuity (VA) worsened to 20/100 OD. IVT treatment was switched to faricimab-svoa injections. After 2 injections, there was significant improvement on optical coherence tomography and in VA (20/60). Conclusions: This case shows the potential therapeutic benefits of targeting angiopoietin-2 in addition to vascular endothelial growth factor to treat PCV refractory to ranibizumab. Faricimab may provide an alternative to therapy with ranibizumab and verteporfin photodynamic therapy for the treatment of PCV.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264241271739"},"PeriodicalIF":0.5000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562463/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of VitreoRetinal Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/24741264241271739","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To report a case of polypoidal choroidal vasculopathy (PCV) recalcitrant to treatment with ranibizumab and with a ranibizumab port delivery system (Susvimo) but responsive to faricimab-svoa. Methods: A case and its findings were analyzed. Results: A 69-year-old Filipino man with PCV in the left eye was treated for 2 years with multiple ranibizumab intravitreal (IVT) injections followed by ranibizumab port delivery combined with rescue ranibizumab IVT injections, with no significant response clinically or on imaging. The visual acuity (VA) worsened to 20/100 OD. IVT treatment was switched to faricimab-svoa injections. After 2 injections, there was significant improvement on optical coherence tomography and in VA (20/60). Conclusions: This case shows the potential therapeutic benefits of targeting angiopoietin-2 in addition to vascular endothelial growth factor to treat PCV refractory to ranibizumab. Faricimab may provide an alternative to therapy with ranibizumab and verteporfin photodynamic therapy for the treatment of PCV.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

法利珠单抗治疗对玻璃体内注射雷珠单抗和雷珠单抗门给药(Susvimo)耐药的多形性脉络膜血管病。

目的：报告一例使用雷尼珠单抗和雷尼珠单抗端口输送系统（Susvimo）治疗无效，但使用法替单抗-voa治疗有反应的多形性脉络膜血管病（PCV）病例。方法：分析一个病例及其研究结果。结果：一名 69 岁的菲律宾男子左眼患有 PCV，在接受多次雷尼珠单抗玻璃体内注射（IVT）治疗 2 年后，又接受了雷尼珠单抗端口给药联合雷尼珠单抗 IVT 挽救性注射治疗，但临床和影像学均无明显反应。视力（VA）恶化至 20/100 OD。IVT 治疗改为法尼单抗-voa 注射。两次注射后，光学相干断层扫描和视力（20/60）均有明显改善。结论：该病例表明，在治疗雷尼珠单抗难治的 PCV 时，除了血管内皮生长因子外，靶向血管生成素-2 也具有潜在的治疗优势。法利珠单抗可替代雷尼珠单抗和verteporfin光动力疗法治疗PCV。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of VitreoRetinal Diseases

CiteScore

1.20

自引率

16.70%

发文量